Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
meningococcal A and C conjugate vaccine
- Development stage
- Unknown
- Lead developer
- Serum Institute of India
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The meningococcal A and C conjugate vaccine is an inactivated vaccine comprising purified capsular polysaccharide antigens from *Neisseria meningitidis* serogroups A and C, each covalently linked (conjugated) to a carrier protein (typically diphtheria or tetanus toxoid or CRM197 protein)[1][4][5]. The conjugation enhances immunogenicity, especially in infants and young children, by inducing T cell–dependent immune responses. When administered, the vaccine induces the production of specific antibodies (IgG, IgM, and IgA) against *N. meningitidis* serogroups A and C, providing active immunity against invasive infections caused by these serogroups. It is primarily indicated for the prevention of invasive meningococcal diseases, such as meningococcal meningitis, caused by these specific serogroups, especially in populations at increased risk or in response to outbreaks[1][4][5].
- Other names
- meningococcal A + C conjugate vaccineMenA+C conjugate vaccineNeisseria meningitidis group A and C conjugate vaccine
02
Targets
NmA CPS (Neisseria meningitidis group A capsular polysaccharide)Neisseria meningitidis group C capsular polysaccharide
Beyond the preview
Go deeper on meningococcal A and C conjugate vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on meningococcal A and C conjugate vaccine.